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Abstract
Transcatheter closure of secundum atrial septal defect (ASD) and patent foramen ovale (PFO) is now
widely accepted as an alternative to surgical closure. With currently available devices and techniques,
approximately 80-90% of secundum ASDs and all PFOs can be closed percutaneously. While many
devices are available, the use of any particular device is dictated largely by individual defect anatomy,
device availability, long-term considerations, approval status (US Food and Drug Administration
approval versus CE mark), and physician preference.
Introduction and context
Since the pioneering work of King and Mills in 1974 [1],
numerous devices to close atrial septal defects (ASDs)
have been developed and implanted. Several studies
have shown that transcatheter closure of the vast
majority of secundum ASDs and patent foramen ovales
(PFOs) is as safe and effective as the surgical approach. In
the US, the Amplatzer septal occluder (ASO) (AGA
Medical Corporation, Plymouth, MN, USA) and HELEX
septal occluder (W.L. Gore & Associates, Inc., Flagstaff,
AZ, USA) are the only ASD closure devices approved by
the US Food and Drug Administration (FDA). A non-
randomized trial in the US using the ASO [2] and the US
multi-center pivotal trial [3] (using the HELEX septal
occluder) both demonstrated transcatheter ASD closure
to be equivalent to surgical ASD closure in terms of
clinical efficacy and overall safety in patients with
suitable anatomy. Though not approved in the US for
ASD closure, many other transcatheter occluders are
approved for human use throughout the world. In our
practice and in other published series, only about 10-
20% of patients with a secundum ASD cannot undergo
successful transcatheter ASD closure because of anatomic
factors such as deficiency of a portion of the rim of the
defect or extremely large size of the defect [4].
There has been a growing trend toward closing PFO in
patients who are at high risk for recurrent paradoxical
emboli, especially those with an embolic stroke and no
other identifiable predisposing factor. We feel that
current evidence indicates that PFO closure and medical
management have relatively similar efficacy in reducing
the risk of recurrent strokes in patients who have suffered
an otherwise unexplained stroke. This sense of equipoise
is the underlying principle allowing more detailed
prospective randomized comparisons of the two strate-
gies. Currently, in the US, no device has been approved
by the FDA for PFO closure specifically as the first
randomized prospective trials will not be completed
until sometime in 2010. Devices approved for ASD or
ventricular septal defect closure, however, are widely
used off-label to close PFO in high-risk patients who,
hopefully, have been appropriately counseled about the
current state of evidence and the alternatives. While
percutaneous ASD and PFO closures are safe and
effective alternatives to surgery in the short and inter-
mediate term, long-term data comparable to surgical
closure are lacking, specifically regarding the effects on
the heart of a permanent implant in the atrial septum.
Recent advances
While device closure of PFOs and select ASDs has been
s h o w nt ob es a f ea n de f f e c t i v ei nt h es h o r tt e r m
compared with surgical closure, the serious complication
of cardiac perforation or erosion has been identified as a
concern not seen in early studies. Though rare, this
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Erosions from the ASO, the most widely used ASD
closure device worldwide, have been estimated at 0.1%
or less. Factors predisposing to erosion are not well
understood because of the rarity of the complication and
limited available data. Device over-sizing was the first
potential factor implicated with limited data and led to
revised guidelines regarding sizing of ASO devices [5].
There remains, however, considerable controversy
regarding the mechanisms of erosion. El-Said and
Moore [6] recently concluded from a survey that the
majority of the members of a large consortium of
interventional cardiologists specializing in treatment of
structural heart disease felt that ‘motion’ of the device
was a primary factor in erosions rather than device over-
sizing. Moreover, recent findings suggest that implanta-
tion of an ASD device may lead to more geometric
changes in surrounding cardiac structures than pre-
viously had been thought [7].
We have personally been struck by the surprisingly
dynamic nature of the atrial septum and the variability in
ASD dimensions during the cardiac cycle. In fact, the size
of an ASD has been found to change significantly during
different phases of the cardiac cycle – by as much as an
86% change in area in some patients [8-10]. This
contractility and motion of the atrial septum may be
important in the interaction of septal closure devices
with the atrial septum and adjacent structures. No case of
cardiac perforation has been reported with the HELEX
device (the other device approved in the US), but this
device is used only in small- and medium-sized defects
and the experience with this device is limited because it
was only recently approved by the FDA. In addition, this
device may develop one or more fractures of the
supporting frame in a small percentage of cases. While
these fractures are almost universally not associated with
clinical consequences, there has been a single case of
damage to the mitral valve [11]. Frame fractures of the
HELEX septal occluder may be a related to atrial
compressive forces as well [11,12].
The focus of much of the recent work on ASD and PFO
device development has been driven by the hypothesis
that leaving a foreign implant behind might not be the
ideal way to close these defects. The BioSTAR septal
repair implant (NMT Medical, Inc., Boston, MA, USA) is
a bioabsorbable device, the bulk of which is made of
acellular porcine intestinal collagen cellular matrix. This
material has been shown to be absorbed and replaced
with native tissue within 2 years. The phase 1 clinical trial
of the BioSTAR Evaluation Study [13] showed excellent
closure rates for PFOs and ASDs, and the investigators
hypothesize that the advantages to such a device are less
potential for thrombus formation, erosion, and arrhyth-
mias and better accessibility to the left atrium if needed
in the future. Another modality currently being evaluated
is closure of PFOs without implants. The Paradigm 1
clinical study by Sievert et al. [14] used the PFx closure
system (Cierra, Inc., Redwood City, CA, USA), which
delivers radiofrequency energy to ‘weld’ the two sides of
the atrial septum together. Although the study demon-
strated feasibility and safety of the technique, closure
rates were far less than those reported with current
alternative PFO closure devices.
Understanding of the anatomy of the atrial septum and
its relationship to important adjacent structures is a
pivotal part of ASD and PFO closure. In recent years,
imaging during the procedure with intracardiac echocar-
diography (ICE) has proven to be a safe and effective
alternative to transesophageal echocardiodgraphy (TEE)
in select patients. ICE has been shown to decrease
procedure times while avoiding the need for general
anesthesia in many patients [15]. This is our preferred
adjunct imaging modality (in addition to fluoroscopy)
in appropriate-sized patients. Moreover, it may be used
in addition to TEE to guide closure of defects with
difficult anatomy. Despite advances in imaging mod-
alities (i.e., ICE), we feel that fluoroscopy remains an
important part of the procedure and allows the operator
to assess the anatomy of the defect (by angiography and
balloon occlusion) and the configuration of the device in
various imaging planes.
Implications for clinical practice
Percutaneous device closure of ASD and PFO has proven
to be an excellent alternative to surgical closure in the
majority of affected patients. The percutaneous approach
is clearly preferred by nearly all patients since it is an
outpatient procedure that is much less painful and does
not result in a lifelong visible scar. In centers with
qualified interventionalists, over 80% of affected
patients are treated with the percutaneous approach.
However, operator and center experience are important
considerations as increased short-term risks in adults do
seem to correlate with the relatively lower number of
procedures performed at centers annually [16]. While
percutaneous device closure of secundum ASD and PFO
provides overall excellent clinical results in short- to
medium-term studies, there are few data on long-term
outcomes and possible complications. FDA-mandated
post-market surveillance studies, which are currently
under way, may help to better characterize long-term
risks. Although transcatheter ASD closure devices from
only two manufacturers have been approved in the US,
there are many other designs in various stages of
development and use around the world. For any given
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related to technical aspects, device profile, and retrieva-
bility. Though still experimental, newer technologies
aimed at leaving little or no foreign material behind
remain promising alternatives for the future.
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